Cargando…

Alternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: a systematic review with meta-analysis

BACKGROUND: Alternative lengthening of telomeres (ALT) is a telomerase-independent mechanism used by a broad range of neoplasms to maintain telomere length, permitting uncontrolled replication during their progression. ALT has been described in different types of sarcoma, but a comprehensive analysi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lawlor, Rita T., Veronese, Nicola, Pea, Antonio, Nottegar, Alessia, Smith, Lee, Pilati, Camilla, Demurtas, Jacopo, Fassan, Matteo, Cheng, Liang, Luchini, Claudio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419345/ https://www.ncbi.nlm.nih.gov/pubmed/30871494 http://dx.doi.org/10.1186/s12885-019-5424-8

Ejemplares similares

Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?
por: Luchini, Claudio, et al.
Publicado: (2021)

The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype
por: Amorim, João P., et al.
Publicado: (2016)

ATR Inhibition Broadly Sensitizes Soft-Tissue Sarcoma Cells to Chemotherapy Independent of Alternative Lengthening Telomere (ALT) Status
por: Laroche-Clary, Audrey, et al.
Publicado: (2020)

Alternative lengthening of telomeres (ALT) in cancer stem cells in vivo
por: Bojovic, Bojana, et al.
Publicado: (2014)

Alternative Lengthening of Telomeres (ALT) in Tumors and Pluripotent Stem Cells
por: Zhao, Shuang, et al.
Publicado: (2019)

The Molecular Mechanisms and Therapeutic Prospects of Alternative Lengthening of Telomeres (ALT)
por: Sohn, Eric J., et al.
Publicado: (2023)

Single-molecule analysis of subtelomeres and telomeres in Alternative Lengthening of Telomeres (ALT) cells
por: Abid, Heba Z., et al.
Publicado: (2020)

Alternative lengthening of telomeres (ALT) cells viability is dependent on C-rich telomeric RNAs
por: Rosso, Ilaria, et al.
Publicado: (2023)

Signalling inhibition by ponatinib disrupts productive alternative lengthening of telomeres (ALT)
por: Kusuma, Frances Karla, et al.
Publicado: (2023)

Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT)
por: De Vitis, Marco, et al.
Publicado: (2018)

ALT control, delete: FANCM as an anti-cancer target in Alternative Lengthening of Telomeres
por: O’Rourke, Julienne J, et al.
Publicado: (2019)

MEDB-68. Analysis of telomeres length and Alternative Lengthening of Telomeres (ALT) in molecular subgroups of infant medulloblastoma
por: Buttarelli, Francesca Romana, et al.
Publicado: (2022)

TCGA Pan-Cancer Genomic Analysis of Alternative Lengthening of Telomeres (ALT) Related Genes
por: Armendáriz-Castillo, Isaac, et al.
Publicado: (2020)

ALT-FISH quantifies alternative lengthening of telomeres activity by imaging of single-stranded repeats
por: Frank, Lukas, et al.
Publicado: (2022)

Potential clinical treatment prospects behind the molecular mechanism of alternative lengthening of telomeres (ALT)
por: Sun, Haolu, et al.
Publicado: (2023)

Alternative Lengthening of Telomeres Is Rare in Canine Histiocytic Sarcoma
por: Kreilmeier-Berger, Theresa, et al.
Publicado: (2023)

CD200 expression is a feature of solid pseudopapillary neoplasms of the pancreas
por: Lawlor, Rita T., et al.
Publicado: (2018)

The FANCM-BLM-TOP3A-RMI complex suppresses alternative lengthening of telomeres (ALT)
por: Lu, Robert, et al.
Publicado: (2019)

Epigenetic Characteristics of Human Subtelomeres Vary in Cells Utilizing the Alternative Lengthening of Telomeres (ALT) Pathway
por: Toubiana, Shir, et al.
Publicado: (2021)

Prognostic Role of High-Grade Tumor Budding in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis with a Focus on Epithelial to Mesenchymal Transition
por: Lawlor, Rita T., et al.
Publicado: (2019)

Author Correction: The FANCM-BLM-TOP3A-RMI complex suppresses alternative lengthening of telomeres (ALT)
por: Lu, Robert, et al.
Publicado: (2019)

Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size
por: Hackeng, Wenzel M, et al.
Publicado: (2022)

Alternative lengthening of telomeres: remodeling the telomere architecture
por: Conomos, Dimitri, et al.
Publicado: (2013)

Alternative Lengthening of Telomeres and Mediated Telomere Synthesis
por: Hou, Kailong, et al.
Publicado: (2022)

Detection of alternative lengthening of telomeres by telomere quantitative PCR
por: Lau, Loretta M. S., et al.
Publicado: (2013)

ATRX represses alternative lengthening of telomeres
por: Napier, Christine E., et al.
Publicado: (2015)

Alternative Lengthening of Telomeres and Chromatin Status
por: Udroiu, Ion, et al.
Publicado: (2019)

Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT)
por: Falcinelli, Marta, et al.
Publicado: (2023)

Histo-molecular oncogenesis of pancreatic cancer: From precancerous lesions to invasive ductal adenocarcinoma
por: Riva, Giulio, et al.
Publicado: (2018)

Alternative Lengthening of Telomeres is characterized by reduced compaction of telomeric chromatin
por: Episkopou, Harikleia, et al.
Publicado: (2014)

G-quadruplexes mark alternative lengthening of telomeres
por: Yang, Sunny Y, et al.
Publicado: (2021)

Telomeric replication stress: the beginning and the end for alternative lengthening of telomeres cancers
por: Lu, Robert, et al.
Publicado: (2022)

The alternative lengthening of telomeres mechanism jeopardizes telomere integrity if not properly restricted
por: Silva, Bruno, et al.
Publicado: (2022)

Pan-Cancer Analysis of Alternative Lengthening of Telomere Activity
por: Sung, Ji-Yong, et al.
Publicado: (2020)

Alternative Lengthening of Telomeres in the Budding Yeast Naumovozyma castellii
por: Cohn, Marita, et al.
Publicado: (2019)

Alternative Lengthening of Telomeres in Pediatric Cancer: Mechanisms to Therapies
por: Kent, Thomas, et al.
Publicado: (2020)

Alternative lengthening of telomeres is not synonymous with mutations in ATRX/DAXX
por: de Nonneville, Alexandre, et al.
Publicado: (2021)

Detection of alternative lengthening of telomeres mechanism on tumor sections
por: Claude, Eloïse, et al.
Publicado: (2021)

ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner
por: Brosnan-Cashman, Jacqueline A., et al.
Publicado: (2018)

The C-Circle Biomarker Is Secreted by Alternative-Lengthening-of-Telomeres Positive Cancer Cells inside Exosomes and Provides a Blood-Based Diagnostic for ALT Activity
por: Chen, Yuan-Yin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eg9hg2k5df4o11prq4dmdr2qi6